# A Study of GC101 TIL in Advanced Melanoma

Source: https://onco.cc/trials/nct06703398/  
OnCo record `nct06703398` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of GC101 TIL, Dacarbazine, Temozolomide in melanoma, run by Shanghai Juncell Therapeutics, now recruiting.

## Summary

A Study of GC101 TIL in Advanced Melanoma is a phase 2 interventional study registered as NCT06703398 by Shanghai Juncell Therapeutics, with 98 participants planned, started 2024-12-20 and due to reach its primary completion in 2026-05-12. Interventions recorded: GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06703398
- Phase: 2
- Setting: A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma
- Sponsor: Shanghai Juncell Therapeutics
- Enrolled: 98

## Sources

- ClinicalTrials.gov NCT06703398: https://clinicaltrials.gov/study/NCT06703398

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Dacarbazine](https://onco.cc/drugs/dacarbazine/), [GC101 TIL](https://onco.cc/drugs/gc101-til/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Shanghai Juncell Therapeutics](https://onco.cc/companies/shanghai-juncell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06703398.json